5:39 PM
 | 
May 14, 2013
 |  BC Extra  |  Company News

FDA expands Tarceva label, approves companion diagnostic

FDA approved an sNDA from Astellas Pharma Inc. (Tokyo:4503) on Tuesday to expand the label for Tarceva erlotinib and also approved the cobas EGFR Mutation Test from partner Roche (SIX:ROG; OTCQX:RHHBY) as a companion diagnostic for the...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >